Market Research Report
Global Breast Cancer Screening and Diagnostic Techniques Market - 2021-2028
|Global Breast Cancer Screening and Diagnostic Techniques Market - 2021-2028|
Published: October 11, 2021
Content info: 180 Pages
Delivery time: 2 business days
The global breast cancer screening and diagnostic techniques market size was valued US$ YY billion in 2019 and is estimated to reach US$ YY billion by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).
Breast cancer screening is carried out to detect cancer in its early stages and ensure the timely treatment to the patients. Early diagnosis is a key to a successful breast cancer treatment. Breast cancer can be diagnosed early by screening tests like yearly mammograms, CT scans, and MRI. Once the symptoms are visually detectable, an individual is advised to undergo a diagnostic test to confirm the suspects of breast cancer.
The breast cancer screening and diagnostic techniques market growth is driven by the rising prevalence of breast cancer coupled with the emergence of novel therapies, increasing awareness about the early detection of breast cancer, and the increasing government initiatives and support. Early detection of cancer also helps in increasing the survival rate, better life quality, and improved treatment options. Moreover, increased intensive research and development in the field of cancer, technological advancements are key factors to drive the growth of the market.
The rising prevalence of breast cancer coupled with the rise in the emergence of new technologies in early screening and diagnosis, is expected to drive the global breast cancer screening and diagnostic techniques market growth
The incidence of breast cancers is proliferating. According to the World Health Organization (WHO) scenario, breast cancer is the second most cancer occurring among women. It affects nearly 2.1 million women each year. According to the American Cancer Society, around 281,550 women are projected to be diagnosed with breast cancer in 2021, and 43,600 women are predicted to die from breast cancer in the US. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed and only about 10% to 15% of cases occur in women younger than 45 years of age.
In addition, the rise in the emergence of new technologies in early screening and diagnosis for breast cancer is also driving the growth of the breast cancer diagnostics market globally. For instance, on July 10th, 2019, Arizona-based SimonMed Imaging announced its implementation of the first U.S. Food and Drug Administration (FDA)-cleared artificial intelligence (AI) program for significantly enhancing early breast cancer detection for 3-D mammography. The AI program, called ProFound AI for digital breast tomosynthesis (DBT), was developed by iCAD Inc.
The growing demand for technologically advanced products that can enable better accuracy, speed, and cost-effectiveness is likely to be the dominant growth factor over the forecast period. For instance, the introduction of Direct-To-Consumer (DTC) testing in the field of cancer diagnostics. The first DTC test, introduced in 2018 by 23andMe, received U.S. FDA approval for BRCA testing. It is one of the first DTC tests for the BRCA gene mutations that increase the risk of breast and ovarian cancers. In April 2019, Hologic, Inc. launched the Trident® HD specimen radiography system, a next-generation solution that delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies.
Besides, the increasing reimbursement and insurance coverage are expected to increase the adoption of testing. Government agencies are approving different tests for nationwide reimbursement. Medicaid, Medicare, and third-party payer benefit plans in the U.S. cover the cost of genetic testing. Genetic tests, such as BRCA1 and BRCA2, are reimbursed by most health plans for individuals with a family history of cancer, which has led to a rise in the number of tests being carried out.
However, costly follow-ups for diagnosis, limited availability and stringent regulatory framework are some of the factors hampering the growth of the breast cancer screening and diagnostic technique market globally. For instance, mammography costs around $200 and approx. 50% of women are poorly diagnosed. There is also limited access to current cancer screening methods in Eastern Europe, Asia and Africa due to the high cost of diagnostic imaging equipment outlays. High false-positive cancer diagnosis rates and indeterminate mammograms requiring follow-up with MRI, 3D mammography, and biopsies are challenges to the market for breast screening and diagnostics.
The COVID-19 pandemic has negatively impacted healthcare systems globally and also on the market growth. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.
Mammograms are the most widely used tests to screen breast cancer. Since mammography is the standard gold technique used to screen breast cancer, governments and other healthcare organizations worldwide are taking initiatives to provide women between 50 and 75 access to mammography screening. A mammogram is an x-ray of the breast that can reveal benign or malignant abnormalities. It is obtained by applying a small dose of radiation through the breast post-compression between two plates to produce an x-ray image. Mammograms can be utilized for both screening and diagnosis. Mammogram screening is performed as an attempt to detect any early signs of breast cancer, even before symptoms occur, to decrease mortality by early diagnosis. Mammography facilities in the United States and its territories (including military bases) are subject to the Mammography Quality Standards Act (MQSA). The act requires annual inspections and accreditation every three years through an FDA-approved body. Key players are collaborating to innovate new technological tests to diagnose breast cancer. For instance, on July 25th, 2019, Hologic partnered with mammography information solutions provider MagView to develop Unifi EQUIP, an automated solution that will facilitate compliance with the U.S. Food and Drug Administration's (FDA) Enhancing Quality Using the Inspection Program (EQUIP) guidance. This increases the global demand for mammography. Digital breast tomosynthesis can increase the diagnostic accuracy of mammography and is used for the assessment of equivocal or suspicious mammography findings. Other modalities, such as ultrasound and contrast-enhanced magnetic resonance imaging (MRI), play an important role in breast cancer diagnostics, staging, and follow-up.
The hospitals and clinics segment dominated the market for breast cancer screening and diagnostics market. The increasing hospitalization of patients and the growing burden of the disease are expected to propel the segment's growth. After the screening test, patients undergo a biopsy for confirmatory testing in hospitals. For instance, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2020, there were 7.8 million women alive who have been diagnosed with breast cancer in the past 5 years, making it the world's most prevalent cancer. Moreover, PET, CT, and MRI are used to check disease progression and assess the effectiveness of cancer treatment.
Further, governments have increased the number of initiatives to provide various services, such as reimbursement for diagnostic tests. Many healthcare institutions work with laboratories to integrate different tests, such as mammography, ultrasound, and MRI.
North America dominates the breast cancer screening and diagnostics market due to rising breast cancer cases and increasing technological advancements for cancer diagnosis. For instance, about 1 in 8 U.S. women (about 12%) will develop invasive breast cancer over the course of their lifetime. In 2019, an estimated 268,600 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S., along with 62,930 new cases of non-invasive (in situ) breast cancer. About 2,670 new cases of invasive breast cancer are expected to be diagnosed in men in 2019. A man's lifetime risk of breast cancer is about 1 in 883.
In addition, increasing initiatives taken by the manufacturers to create awareness about breast cancer are driving the market's growth in this region. For instance, in July 2019, Fujifilm Medical Systems USA has launched a nationwide effort to enhance access to breast cancer screening and raise awareness about the importance of early disease detection. Called "Aspire to Be Fearless," the 18-month, 48-state campaign features a mobile mammography bus that will travel around the country to educate local communities and offer mammograms. New product developments, acquisitions, collaborations, and regional expansions are some of the key strategic initiatives major players undertake to maintain stability in the market. For instance, In July 2019, Exact Sciences Corp and Genomic Health Inc. entered into a definitive agreement in which these companies will create a leading global cancer diagnostics company. The combined company will offer two of the strongest and fastest-growing brands in cancer diagnostics, Cologuard and Oncotype DX.
The global breast cancer screening and diagnostic techniques market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Allengers, Myriad Genetics, Inc, Siemens Healthcare GmbH, GE Healthcare, Hologic Inc, Abbott Laboratories, QIAGEN, Paragon Biosciences LLC, Quest Diagnostics Incorporated. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, In July 2019, Paragon Biosciences launched the seventh portfolio company, Qlarity Imaging LLC, which was founded to harness the value of artificial intelligence (AI) to improve medical outcomes.
In May 2019, QIAGEN launched its first FDA-approved companion diagnostic for PIK3CA biomarkers to enhance precision medicine in breast cancer.
The global breast cancer screening and diagnostic techniques market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.